Focus: BioStem Technologies is a publicly traded biotechnology company focused on perinatal tissue-derived products for regenerative medicine applications, currently in early clinical development with a narrow but specialized market focus.
Profile data last refreshed 10h ago · AI intelligence enriched 2w ago
Growing — net +5 jobs in 30d
6 jobs added vs 1 removed. Steady team buildout.
Best suited for early-stage biotech risk-takers seeking ground-floor equity upside in a niche regenerative medicine company, with caution around cash burn and timeline to market.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for BioStem Technologies
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from BioStem Technologies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
BioStem Technologies files Form 10 to pursue Nasdaq uplisting - scanx.trade
BioStem Technologies files Form 10 to pursue Nasdaq uplisting scanx.trade
BioStem Technologies Announces Issuance of Four U.S. Design Patents Covering Fenestrated Human Placental Allograft Technologies - guardonline.com
BioStem Technologies Announces Issuance of Four U.S. Design Patents Covering Fenestrated Human Placental Allograft Technologies guardonline.com
BioStem Technologies to Present at the Planet MicroCap Las Vegas 2026 Conference - The Manila Times
BioStem Technologies to Present at the Planet MicroCap Las Vegas 2026 Conference The Manila Times
BioStem Technologies to present at Planet Micro... - Pluang
BioStem Technologies to present at Planet Micro... Pluang
Las Vegas micro-cap forum to feature BioStem on June 17 - Stock Titan
Las Vegas micro-cap forum to feature BioStem on June 17 Stock Titan
BioStem Technologies Names Mark Glickman, Steven Sonenreich and Rayna Hannaway to Board - citybiz
BioStem Technologies Names Mark Glickman, Steven Sonenreich and Rayna Hannaway to Board citybiz
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo